Puma Biotechnology, Inc. (PBYI) |
|
3.09 0.22 (7.67%)
|
03-31 16:00 |
|
Open: |
2.9 |
Pre. Close: |
2.87 |
|
High:
|
3.12 |
Low:
|
2.84 |
|
Volume:
|
547,404 |
Market Cap:
|
149(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:21:10 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 3.97 One year: 4.89 |
| Support: |
Support1: 2.13 Support2: 1.77 |
| Resistance: |
Resistance1: 3.4 Resistance2: 4.19 |
| Pivot: |
2.47  |
| Moving Average: |
MA(5): 2.67 MA(20): 2.55 
MA(100): 3.93 MA(250): 3.14 |
| MACD: |
MACD(12,26): -0.3 Signal(9): -0.4 |
| Stochastic oscillator: |
%K(14,3): 74.6 %D(3): 57.3 |
| RSI: |
RSI(14): 54.9 |
| 52-week: |
High: 5.15 Low: 1.6 |
| Average Vol(K): |
3-Month: 344 (K) 10-Days: 459 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PBYI ] has closed Bollinger Bands are 33.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.12 - 3.13 |
3.13 - 3.14 |
|
Low:
|
2.81 - 2.82 |
2.82 - 2.84 |
|
Close:
|
3.07 - 3.09 |
3.09 - 3.11 |
|
Company Description |
|
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California. |
Headline News |
Fri, 31 Mar 2023
Puma Biotechnology (NASDAQ:PBYI) Lifted to "Buy" at StockNews ... - MarketBeat
Wed, 29 Mar 2023
EXEL: 3 Biotech Stocks Losing Momentum - StockNews.com
Thu, 23 Mar 2023
StockNews.com Lowers Puma Biotechnology (NASDAQ:PBYI) to Hold - MarketBeat
Tue, 14 Mar 2023
Renaissance Technologies LLC reduces its stake in Puma ... - Best Stocks
Tue, 14 Mar 2023
Puma Biotechnology Announces Publication of Phase II Clinical ... - Business Wire
Tue, 07 Mar 2023
Is Puma Biotechnology Inc (PBYI) Stock at the Top of the Biotechnology Industry? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
46 (M) |
| Shares Float |
32 (M) |
|
% Held by Insiders
|
16.9 (%) |
|
% Held by Institutions
|
60.1 (%) |
|
Shares Short
|
936 (K) |
|
Shares Short P.Month
|
1,420 (K) |
Stock Financials |
|
EPS
|
-1.52 |
|
EPS Est Next Qtl
|
-2.12 |
|
EPS Est This Year
|
-8.69 |
|
EPS Est Next Year
|
-4.7 |
|
Book Value (p.s.)
|
-0.16 |
|
Profit Margin (%)
|
4.5 |
|
Operating Margin (%)
|
12.6 |
|
Return on Assets (ttm)
|
8.1 |
|
Return on Equity (ttm)
|
175 |
|
Qtrly Rev. Growth
|
23.5 |
|
Gross Profit (p.s.)
|
4.51 |
|
Sales Per Share
|
4.69 |
|
EBITDA (p.s.)
|
0.78 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-29 (M) |
|
Levered Free Cash Flow
|
-19 (M) |
Stock Valuations |
|
PE Ratio
|
-2.04 |
|
PEG Ratio
|
0.2 |
|
Price to Book value
|
-20.6 |
|
Price to Sales
|
0.65 |
|
Price to Cash Flow
|
-4.95 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
